 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || CEB-01 / Cebiotex
New P2 trial: CEB-01 in Locally Resectable Pancreatic Cancer (clinicaltrials.gov) - Aug 6, 2024
P2, N=21, Recruiting, Sponsor: CEBIOTEX
- CEB-01 / Cebiotex
First-in-human CEB-01: Novel loco-regional SN-38 release membrane to prevent local recurrence in retroperitoneal sarcomas. (Hall A; Poster Bd #: 492) - Apr 24, 2024 - Abstract #ASCO2024ASCO_774;
P1
CEB-01 at 18 mg provides promising local disease control and a local steady and prolonged release of SN-38, with a much lower Cmax than irinotecan. An international phase 2 trial with CEB-01 at 18 mg to demonstrate local control is underway.
- || CEB-01 / Cebiotex
Enrollment closed, Trial completion date, Trial primary completion date, Surgery, Metastases: CEB-01-RLS01-CT: First-in-man Clinical Trial of CEB-01 PLGA Membrane in Recurrent or Locally Advanced Retroperitoneal Soft Tissue Sarcoma (clinicaltrials.gov) - Mar 28, 2024
P1, N=21, Active, not recruiting, Sponsor: CEBIOTEX
An international phase 2 trial with CEB-01 at 18 mg to demonstrate local control is underway. Recruiting --> Active, not recruiting | Trial completion date: Mar 2024 --> May 2025 | Trial primary completion date: Dec 2023 --> May 2025
- CEB-01 / Cebiotex
First in human trial of CEB-01 for retroperitoneal soft tissue sarcoma () - Jul 27, 2023 - Abstract #ESMO2023ESMO_3377;
P1
Local recurrence occurred in 2 out of 10 pts at 5.5- and 8.6-months post-surgery. CEB-01 provides a local steady and prolonged release of SN-38, with a much lower Cmax than when SN-38 is administered as irinotecan.
- | CEB-01 / Cebiotex
Trial completion date, Trial primary completion date, Surgery, Metastases: CEB-01-RLS01-CT: First-in-man Clinical Trial of CEB-01 PLGA Membrane in Recurrent or Locally Advanced Retroperitoneal Soft Tissue Sarcoma (clinicaltrials.gov) - May 8, 2023
P1, N=21, Recruiting, Sponsor: CEBIOTEX
CEB-01 provides a local steady and prolonged release of SN-38, with a much lower Cmax than when SN-38 is administered as irinotecan. Trial completion date: Apr 2023 --> Mar 2024 | Trial primary completion date: Mar 2023 --> Dec 2023
- | CEB-01 / Cebiotex
Trial completion date, Trial primary completion date, Surgery, Metastases: CEB-01-RLS01-CT: First-in-man Clinical Trial of CEB-01 PLGA Membrane in Recurrent or Locally Advanced Retroperitoneal Soft Tissue Sarcoma (clinicaltrials.gov) - Jul 27, 2022
P1, N=21, Recruiting, Sponsor: CEBIOTEX
Trial completion date: Apr 2023 --> Mar 2024 | Trial primary completion date: Mar 2023 --> Dec 2023 Trial completion date: Apr 2022 --> Apr 2023 | Trial primary completion date: Mar 2022 --> Mar 2023
- CEB-01 / Cebiotex
Surgical implantation of CEB-01, novel drug delivery matrix, in patients with recurrent or locally advanced retroperitoneal soft tissue sarcoma (RPS) () - Nov 29, 2021 - Abstract #ESSO2021ESSO_479;
- CEB-01 / Cebiotex
[VIRTUAL] Cebiotex Biomedical Nanofibers () - May 31, 2021 - Abstract #BIO2021BIO_286;
Future perspective of CEBIOTEX® Technological Platform is to also provide solutions to patients who suffer from other cancer indications and other therapeutical applications as infections or advanced therapies for marrow and cartilage regeneration, marrow injuries, ... More information at www.cebiotex.com/en/
- CEB-01 / Cebiotex
[VIRTUAL] First-in-human administration of CEB-01, a novel drug delivery implant matrix, in patients with recurrent or locally advanced retroperitoneal soft tissue sarcoma (RPS) after surgery: Preliminary safety and pharmacokinetics report. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1172;
P1
Preliminary PK indicates low, prolonged, systemic SN-38 exposure as expected . Currently the second cohort of this trial is open for recruitment.
- | CEB-01 / Cebiotex
New P1 trial, Surgery, Metastases: CEB-01-RLS01-CT: First-in-man Clinical Trial of CEB-01 PLGA Membrane in Recurrent or Locally Advanced Retroperitoneal Soft Tissue Sarcoma (clinicaltrials.gov) - Nov 5, 2020
P1, N=21, Recruiting, Sponsor: CEBIOTEX